摘要
目的分析兰索拉唑联合莫沙必利治疗反流性食管炎的临床疗效。方法 102例反流性食管炎患者,随机分为对照组和实验组,各51例。对照组采用兰索拉唑治疗,实验组采用兰索拉唑联合莫沙必利治疗。对比两组患者的治疗效果、不良反应发生情况及临床症状评分、生活质量评分。结果实验组治疗总有效率98.04%高于对照组的86.27%,差异具有统计学意义(P<0.05)。实验组不良反应发生率1.96%低于对照组的15.69%,差异具有统计学意义(P<0.05)。实验组反流评分为(0.21±0.09)分、胸痛评分为(0.16±0.07)分、上腹部疼痛评分为(0.23±0.08)分、胸骨后烧灼感评分为(0.44±0.01)分,均明显低于对照组的(1.34±0.39)、(1.25±0.35)、(1.13±0.21)、(0.97±0.15)分,差异具有统计学意义(P<0.05)。实验组社会关系、精神状态、躯体功能、生理功能评分分别为(64.38±0.69)、(61.79±0.68)、(72.45±0.78)、(76.31±2.08)分,均高于对照组的(55.13±0.92)、(52.23±1.14)、(53.05±1.15)、(59.65±7.23)分,差异具有统计学意义(P<0.05)。结论对反流性食管炎患者实施兰索拉唑联合莫沙必利治疗,其临床效果显著,不良反应少,能够有效改善患者的生活质量,具有应用及推广价值。
Objective To analyze the clinical efficacy of lansoprazole combined with mosapride in the treatment of reflux esophagitis. Methods A total of 102 patients with reflux esophagitis were randomly divided into control group and experimental group, with 51 cases in each group. The control group was treated with lansoprazole, and the experimental group was treated with lansoprazole combined with mosapride. The therapeutic effect, occurrence of adverse reactions, clinical symptom score and quality of life score were compared between the two groups. Results The total effective rate 98.04% of the experimental group was higher than 86.27% of the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions 1.96% of the experimental group was lower than 15.69% of the control group, and the difference was statistically significant(P<0.05). The reflux score(0.21±0.09) points, chest pain score(0.16±0.07) points, upper abdominal pain score(0.23±0.08) points, poststernal burning sensation score(0.44±0.01) points of the experimental group were significantly lower than(1.34±0.39),(1.25±0.35),(1.13±0.21),(0.97±0.15) points of the control group, and the difference was statistically significant(P<0.05). The scores of social relationship, mental state, physical function and physiological function of the experimental group were(64.38±0.69),(61.79±0.68),(72.45±0.78) and(76.31±2.08) points, which were higher than(55.13±0.92),(52.23±1.14),(53.05±1.15) and(59.65± 7.23) points of the control group, and the difference was statistically significant(P<0.05). Conclusion Lansoprazole combined with mosapride shows remarkable clinical effect on patients with reflux esophagitis, and the adverse reactions was few. It can effectively improve the quality of life of patients, and has application and promotion value.
作者
王静
WANG Jing(Dalian Fourth People’s Hospital,Dalian 116031,China)
出处
《中国实用医药》
2021年第7期19-21,共3页
China Practical Medicine
